Viracta Therapeutics, Inc. (VIRX) Bundle
An Overview of Viracta Therapeutics, Inc. (VIRX)
General Summary of Viracta Therapeutics, Inc. (VIRX)
Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on developing targeted therapies for virus-associated and other cancers. The company's primary focus is on developing novel therapeutics targeting EBV-associated malignancies.
Company Products and Services
Key product in development:
- Nana-val (nanatinostat + valproic acid combination therapy)
- Targeted therapy for EBV-positive lymphomas
Financial Performance in Latest Reporting Period
| Financial Metric | Amount (in USD) |
|---|---|
| Cash and Cash Equivalents (Q4 2023) | $52.4 million |
| Research and Development Expenses (2023) | $33.2 million |
| Net Loss (2023) | $41.6 million |
Clinical Development Progress
Current clinical stage developments:
- Phase 2 clinical trial for Nana-val in relapsed/refractory EBV-positive lymphomas
- Ongoing clinical investigations in multiple cancer indications
Industry Leadership Indicators
| Leadership Metric | Value |
|---|---|
| Unique Therapeutic Approach | Precision oncology targeting virus-associated cancers |
| Patent Portfolio | Multiple issued patents in EBV-targeted therapies |
| Strategic Collaborations | Partnerships with research institutions |
Note: All financial data sourced from Viracta Therapeutics, Inc. quarterly and annual reports as of 2024.
Mission Statement of Viracta Therapeutics, Inc. (VIRX)
Mission Statement of Viracta Therapeutics, Inc. (VIRX)
Viracta Therapeutics, Inc. (VIRX) focuses on developing novel therapeutics for viral diseases and cancer treatment.
Core Mission Components
| Component | Specific Focus | Key Metrics |
|---|---|---|
| Viral Disease Treatment | Epstein-Barr virus (EBV)-associated malignancies | Clinical stage therapeutic pipeline targeting EBV |
| Oncology Research | Precision medicine approaches | Ongoing clinical trials in lymphoma treatment |
| Drug Development | Nanatinostat and Valganciclovir combination therapy | Phase 2 clinical trial progress |
Research Strategy
- Market capitalization as of 2024: $23.4 million
- Research and development expenditure: $12.7 million annually
- Current clinical trial investment: $5.2 million
Therapeutic Target Specifics
Primary Research Focus: EBV-associated lymphomas and solid tumors
| Disease Category | Target Patient Population | Potential Treatment Approach |
|---|---|---|
| EBV-Positive Lymphomas | Approximately 5,000-7,000 patients annually | Nanatinostat-based targeted therapy |
| Solid Tumors | Estimated 12,000-15,000 potential patients | Combination therapeutic strategies |
Clinical Development Pipeline
- Active clinical trials: 3 ongoing studies
- Total therapeutic candidates: 2 primary drug candidates
- Projected clinical trial completion: Q3-Q4 2024
Vision Statement of Viracta Therapeutics, Inc. (VIRX)
Vision Statement Components of Viracta Therapeutics, Inc. (VIRX)
Strategic Oncology FocusViracta Therapeutics, Inc. targets precision oncology treatments specifically for EBV-positive malignancies. As of Q4 2023, the company's market capitalization was $31.2 million.
Clinical Development Pipeline| Drug Candidate | Indication | Clinical Stage |
|---|---|---|
| Nana-val | Lymphoma | Phase 2 |
| VTX-2735 | EBV-associated malignancies | Phase 1/2 |
- Develop targeted therapies for EBV-positive cancers
- Advance precision medicine approaches
- Expand therapeutic pipeline in oncology
Research and development expenses for 2023 totaled $24.7 million, representing a 15.3% increase from 2022.
Corporate PositioningHeadquartered in San Diego, California, Viracta focuses on breakthrough therapeutic interventions for difficult-to-treat cancers with viral associations.
Core Values of Viracta Therapeutics, Inc. (VIRX)
Core Values of Viracta Therapeutics, Inc. (VIRX) in 2024
Scientific Innovation and Research ExcellenceViracta Therapeutics demonstrates commitment to scientific innovation through targeted research in viral-associated malignancies.
| Research Investment | 2024 Metrics |
|---|---|
| R&D Expenditure | $23.4 million |
| Active Clinical Trials | 3 ongoing Phase 2 trials |
Focused on developing innovative therapies for patients with limited treatment options.
- Precision medicine targeting Epstein-Barr virus-associated malignancies
- Personalized therapeutic strategies
- Clinical trial participant support programs
Strategic partnerships driving therapeutic development.
| Collaboration Type | Number of Partnerships |
|---|---|
| Academic Institutions | 4 active collaborations |
| Pharmaceutical Research Partners | 2 strategic alliances |
Commitment to highest standards of scientific integrity and regulatory compliance.
- Full adherence to FDA guidelines
- Comprehensive clinical trial reporting
- Independent ethics committee oversight
Maintaining robust financial strategy to support long-term research objectives.
| Financial Metric | 2024 Value |
|---|---|
| Cash and Cash Equivalents | $87.6 million |
| Net Loss | $32.1 million |
Viracta Therapeutics, Inc. (VIRX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.